A.P. Pharma Receives FDA Complete Response Letter for APF530 |
|
|
|
A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV). The CRL describes the following issues that must be addressed.
“We appreciate the FDA’s thorough review of the APF530 NDA,” stated John B. Whelan, A.P. Pharma’s president and chief executive officer. “While disappointed in today’s notification, we believe that the issues raised in the CRL are addressable, and we remain firmly committed to the successful development of APF530, which we believe will fulfill an important unmet need and improve the lives of patients suffering from CINV. In order to allow us time to carefully address the issues raised in the CRL, we are now projecting product launch for the first half of 2014, versus our prior guidance of the second half of 2013.” Conference Call Details A.P. Pharma will host a conference call on Thursday, March 28, 2013 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). Interested investors may participate in the conference call by dialing (877) 856-1964 (domestic) or (719) 386-0001 (international) and use participant code 135738. In addition, the live conference call is being webcast and can be accessed on the "Calendar of Events" page of the "Investors" section of the Company's website at www.appharma.com . A replay of the webcast will be posted to this same section of the website available approximately two hours after the call. About APF530 A.P. Pharma's lead product, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuation of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company’s proprietary Biochronomer™ drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. Currently available intravenous and oral formulations of granisetron are approved only for the prevention of acute-onset CINV. Granisetron was selected for APF530 because it is widely prescribed by physicians based on a well-established record of safety and efficacy. About A.P. Pharma A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company’s lead product, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. A.P. Pharma resubmitted its New Drug Application (NDA) for APF530 to the U.S. Food and Drug Administration (FDA) in September 2012 and received a Complete Response Letter in March 2013. For further information, please visit the Company's web site at www.appharma.com . Forward-looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including uncertainties associated with the potential approval of APF530 and the potential timing for such approval, if approved at all, the projected timing for the commercial launch of APF530, if approved, as well as risks relating to capital resources and liquidity, satisfactory completion of clinical studies, progress in research and development programs, successful launch and acceptance of new products and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law. |
A.P. Pharma Receives FDA Complete Response Letter
Top 10 Most Recent News Articles
Swim Readiness Depends on Skills, Not Birthdays Alone
A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...
Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench
Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...
Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won
A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...
Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact
A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...
Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders
Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...
Continue Reading
YYForce Security Win Adds Recurring Singapore Revenue Base
A retail-property security mandate rarely makes anyone pound the table, and frankly it should not. Still, YYForce has landed a tangible two-year contract in Singapore worth roughly S$831,120, with subsidiary Uniforce Security Services set to begin work on December 1, 2026. For NASDAQ:YFOR investors, this is the kind of small, operationally real win that deserves a sober...
Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early
Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...
Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap
Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...
Continue Reading
PayPal's New Leadership Map Puts Execution on Trial
Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...
Continue Reading
Millrose Lawsuit Puts Disclosure Discipline in Focus
A supposedly clean homesite-option story has wandered into the legal weeds, and that is exactly where investors need to slow down. A shareholder class action against Millrose Properties alleges the company painted one business model for the market while pursuing a materially different one behind the curtain. That allegation has not been proven in court, and anybody...
Continue ReadingTop 5 Most Recently Viewed Articles
LootBar Enhances Game Recharge with New Security Features
LootBar Redefines Game Recharge Security As players seek a secure method for discounted game top-ups, LootBar has introduced a groundbreaking self top-up feature. This innovative addition empowers gamers to conduct transactions without exposing their account passwords, presenting a safer alternative to traditional recharge methods. A Major Leap Forward in Security The...
Continue Reading
Marriott Bonvoy Unveils Unique Pet-Friendly Travel Program
Introduction to the Pawssible Journey Program Marriott Bonvoy, a beloved travel program from Marriott International, is set to enchant pet owners across Greater China with the introduction of its new initiative called the "Pawssible Journey." This innovative program is founded on three primary experiences: "Paw Stay" themed accommodations, "Paw Play" social interaction...
Continue Reading
Xeriant Unveils Groundbreaking Video Showcasing Fire Safety Innovation
Xeriant Highlights Innovative Fire-Retardant Technology in New Video Xeriant, Inc. (OTCQB: XERI), a pioneering company dedicated to the discovery and commercialization of advanced materials technology, has released a fascinating video that dives into the remarkable performance of their nanotech fire-retardant. This video encapsulates the power of their innovative fire...
Continue Reading
Understanding Blackstone's Recent Options Activity and Trends
Blackstone's Bullish Options Environment Investors looking at Blackstone are seeing some exciting movements in the options market. These activities have been driven by significant investment interest, hinting that major players are optimistic about Blackstone's future. Insight into Trading Patterns Upon reviewing the trading history for Blackstone (NYSE: BX), multiple...
Continue Reading
Top Smart Meter Startups Spotlight: 360Quadrants Key Report
360Quadrants Highlights Smart Meter Startups in 2025 360Quadrants has recently unveiled an insightful report that shines a light on the leading startups and SMEs in the smart meter industry. This comprehensive evaluation showcases both established global players and emerging innovators who are making remarkable strides in market presence, product development, and...
Continue Reading